Feedback on the 2012 edition success

The mobilization of the jury members and the support of the industrial and institutional partners contributed to the success of the 2012 Innovation Prize, meeting the initial objective, i.e. the promotion and the development of winning alliances between biopharmaceutical public and private sectors.


For this 4^th edition, 120 projects from 16 European countries were reviewed.
Eighty one projects were eligible and ranged by different criteria such as scientific quality of the innovations, intellectual and industrial property protection as well as development strategy.

Universal Biotech thanks gratefully its partners:

• French Ministry of Research
• Ipsen Group and LFB Group
• Institutional partners: Institut Pasteur, European Commission, National Research Agency.

The 2012 Innovation Prize was awarded to the Swedish company Immune Therapy Holdings(1) for having developed the novel Tailored Leukapheresis (TLA), a personalized treatment for Immune Mediated Inflammatory Diseases (IMIDs). The Prize awarded the innovative potential, the interest of the finding and the strength of the industrial property of this Swedish research team.

Feedback on the 2011 edition success

The mobilization of the jury members and the support of the industrial and institutional partners contributed to the success of the 2011 Innovation Prize, meeting the initial objective, i.e. the promotion and the development of winning alliances between biopharmaceutical public and private sectors.


For this 3^rd edition, 89 projects from 13 European countries were reviewed.
Forty one projects were eligible and ranged by different criteria such as scientific quality of the innovations, intellectual and industrial property protection as well as development strategy.

Universal Biotech thanks gratefully its partners:

• French Ministry of Research
• Merck Sharp & Dohme-Chibret laboratory
• Institutional partners: Institut Pasteur, European Commission, National Research Agency.

The 2011 Innovation Prize was awarded to MTP Therapeutics for having developed a new anti-cancer drug for the treatment of solid tumors. The lead compound, called pTM-NRP1, targets Neuropilin-1 receptor and co-receptors which have a pivotal role in endothelial and tumour cell migration. The innovative potential, the interest of the finding and the strength of the industrial property have rewarded the work of this French research team.

2010 edition

Thanks to the active participation of jury members and to the support of industrial partners, the 2010 edition was a real success.

The 2010 Innovation Grant was awarded to XL-Protein, for utilizing its proprietary "PASylation" technology to develop second generation biopharmaceuticals with prolonged plasma half-life.

"PASylation" of therapeutic protiens allows less frequent and lower dosing combined with better tolerability, also opening perspectives for followon products of approved biopharmaceuticals.